scPharmaceuticals Provides Business Update

3/24/20

BURLINGTON, Mass.--(BUSINESS WIRE)--scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced financial results for the fourth quarter and year ended December 31, 2019 and provided a business update.

Business Update

  • Remain on track to resubmit the FUROSCIX New Drug Application (NDA) under the current 505(b)(2) approval pathway with the U.S. Food and Drug Administration (FDA) by mid-year 2020. FUROSCIX is the Company’s lead program for the treatment of congestion in patients with heart failure.
  • Completed summative human factors validation study of the FUROSCIX On-Body Infusor. Two human factors studies were designed to assess and optimize user interaction with the FUROSCIX On-Body Infusor. The summative validation study included 60 participants including congestive heart failure patients, healthcare providers, and caregivers, who collectively represent the intended users of FUROSCIX. Results from the study support the use of the FUROSCIX On-Body Infusor within the intended use population and environments.
  • Device validation and drug stability testing on track to be completed prior to the resubmission of the FUROSCIX NDA. The initial phase of the drug stability study was successfully completed with analytical testing of the drug product batches finalized for the initial timepoints. The Company also accomplished a key aspect of the device validation program in which the adhesive component of the on-body delivery system was shown to be effective in maintaining adherence to the skin of the abdomen in a simulated wear study. Final testing for both the device and drug stability remains on schedule to be completed prior to the resubmission of the FUROSCIX NDA.
  • Commenced initial activities on FUROSCIX pre-commercialization efforts. As development activities for FUROSCIX near completion, the Company has begun to turn attention to pre-commercialization efforts. The Company will be focused on specific pre-commercialization activities including establishing a managed care advisory board, contracting with a specialty pharmacy network, and conducting market research to prepare FUROSCIX product messaging and positioning. These pre-commercialization activities will be staged as appropriate to efficiently follow FUROSCIX’s regulatory progress.

As part of these efforts, the Company participated in Heart Failure Awareness Week, February 9-15, to highlight the limitations of diuretic therapy in heart failure. The campaign, “Drowning in Fluid: The Role of Congestion in Heart Failure” highlights the 3.8 million heart failure events, the 1 to 2 million hospitalizations that occur annually in the U.S., and the opportunity for an outpatient product, like FUROSCIX, to reduce hospital admissions and re-admissions.

“2019 was a very productive year for scPharmaceuticals,” said John Tucker, president and chief executive officer of the Company. “With the completion of our human factors studies and the progress on the final elements of our regulatory submission, we are in a position to resubmit the FUROSCIX NDA to the FDA by mid-year 2020. With the work to resubmit the FUROSCIX NDA nearing completion, we are excited to be now turning our attention to pre-commercialization readiness. FUROSCIX is a product that we believe can transform the treatment of heart failure and improve patient care, reduce hospitalization, and lessen healthcare costs.”

Fourth Quarter and Year End 2019 Financial Results and Financial Guidance

scPharmaceuticals reported a net loss of $10.8 million for the fourth quarter of 2019, compared to $5.1 million for the comparable period in 2018. Research and development expenses were $8.3 million for the fourth quarter of 2019, compared to $3.1 million for the comparable period in 2018. The increase in research and development expenses for the quarter ended December 31, 2019 was primarily due to increased pharmaceutical and device development activities related to the advancement of FUROSCIX. General and administrative expenses were $2.1 million for the fourth quarter ended December 31, 2019 and for the fourth quarter ended December 31, 2018.

scPharmaceuticals reported a net loss of $33.0 million for the year ended December 31, 2019, compared to $29.4 million for the comparable period in 2018. Research and development expenses were $24.6 million for the year ended December 31, 2019, compared to $15.9 million for the comparable period in 2018. The increase in research and development expenses for the year ended December 31, 2019 was primarily due to increased pharmaceutical and device development activities related to the transition to the next generation device and the advancement of FUROSCIX. General and administrative expenses were $8.3 million for the year ended December 31, 2019, compared to $13.7 million for the comparable period in 2018. The decrease was primarily due to the restructuring of the commercial organization mid-year 2018.

scPharmaceuticals ended the fourth quarter with $72.8 million in cash, cash equivalents, and restricted cash compared to $89.7 million as of December 31, 2018. This change reflects the ongoing investment in pharmaceutical and device development. The increase from prior year-end guidance was the result of the Company accessing its at-the-market facility in the quarter ended December 31, 2019, which raised proceeds of $3.9 million, net of commissions.

Based on the Company’s current operating plan, scPharmaceuticals forecasts 2020 expenditures of $9.0 to $11.0 million per quarter. As of December 31, 2019, scPharmaceuticals total shares outstanding was 19,418,955.

About FUROSCIX

FUROSCIX is a proprietary furosemide solution formulated to a neutral pH to allow for subcutaneous infusion via a wearable, pre-programmed on-body drug delivery system, for outpatient self-administration. FUROSCIX is being developed for treatment of congestion, or fluid overload, in patients with heart failure. FUROSCIX has the potential to provide an outpatient alternative for the treatment of worsening heart failure due to congestion.

About scPharmaceuticals

scPharmaceuticals is a pharmaceutical company focused on developing and commercializing products that are designed to reduce healthcare costs and improve health outcomes. The Company develops, internally and through strategic partnerships, innovative products and solutions that aim to expand and advance the outpatient care of select acute conditions. The Company’s lead programs focus on the subcutaneous, self-administration of IV-strength treatments in heart failure and infectious disease. scPharmaceuticals is headquartered in Burlington, MA. For more information, please visit www.scPharmaceuticals.com.